Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study

Flexible care in breast cancer

(2021) A. Wardley et al.   ESMO Open

The oncology hospital at home: Health care utilization outcomes from the huntsman at home trial.

(2020) Kathi Mooney et al.   JOURNAL OF CLINICAL ONCOLOGY

Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study

(2020) Antoinette R Tan et al.   LANCET ONCOLOGY

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

(2019) F Cardoso et al.   ANNALS OF ONCOLOGY

Subcutaneous Injection of Drugs: Literature Review of Factors Influencing Pain Sensation at the Injection Site

(2019) Iris Usach et al.   ADVANCES IN THERAPY

Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019

(2019) H J Burstein et al.   ANNALS OF ONCOLOGY

Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)

(2016) M. Rummel et al.   ANNALS OF ONCOLOGY

A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer

(2016) Erwin De Cock et al.   Cancer Medicine

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

(2014) X. Pivot et al.   ANNALS OF ONCOLOGY

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study

(2013) Xavier Pivot et al.   LANCET ONCOLOGY

Catheter-Associated Thrombosis in Patients With Malignancy

(2009) Sudeep P. Shivakumar et al.   JOURNAL OF CLINICAL ONCOLOGY